Oncolys BioPharma Inc. [4588.T]
TOKYO, May 14 (Pulse News Wire) – Oncolys BioPharma Inc. (4588.T) announced today that the Ministry of Health, Labour and Welfare has scheduled a meeting of the Pharmaceuticals and Medical Devices Agency's Regenerative Medicine Products and Biotechnology Subcommittee for May 21.
The subcommittee will review the manufacturing and marketing approval for the cancer-dissolving virus OBP-301 (Suratadenoturev). Approval discussions will cover whether OBP-301 meets criteria for conditional or time-limited approval. Despite this pending decision, Oncolys BioPharma expects no impact on its fiscal year ending December 2026 financial results.
The company remains committed to launching OBP-301 for esophageal cancer treatment as planned during the same period. OBP-301 was submitted for approval as a regenerative medical product on December 15, 2025. Should approval be granted, Oncolys BioPharma plans to commence sales of OBP-301 for esophageal cancer patients in accordance with their initial timeline.
🟢 Confidence: High AI-translated content.